MGB Biopharma
Developing their completely new class of anti-infective medicine, starting with antibiotics based on Minor Groove Binder (MGBs) compounds.
Launch date
Employees
Market cap
-
Enterprise valuation
AUD11—16m (Dealroom.co estimates Sep 2018.)
Company register number SC362273
Glasgow Scotland (HQ)
Financials
Estimates*
| GBP | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 |
|---|---|---|---|---|---|---|---|
| Revenues | <1m | <1m | <1m | <1m | 1.4m | 1.3m | - |
| % growth | - | 5858 % | (100 %) | 5444 % | 640 % | (4 %) | - |
| EBITDA | (<1m) | (1.2m) | (<1m) | (<1m) | (1.0m) | (1.1m) | (<1m) |
| % EBITDA margin | (7182 %) | (145 %) | (29883 %) | (387 %) | (74 %) | (85 %) | - |
| Profit | (<1m) | (1.1m) | (<1m) | (<1m) | (<1m) | (1.0m) | (<1m) |
| % profit margin | (6294 %) | (130 %) | (24908 %) | (314 %) | (73 %) | (80 %) | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
$3.0m | Series A | ||
£1.3m | Grant | ||
$6.4m | Series B | ||
* | €1.1m | Early VC | |
£2.8m | Grant | ||
£1.3m | Early VC | ||
* | N/A | Late VC | |
| Total Funding | AUD27.3m | ||
Related Content
Recent News about MGB Biopharma
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.